NextCure
NXTC
17 hedge funds and large institutions have $5.03M invested in NextCure in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 11 reducing their positions, and 13 closing their positions.
5.53% less ownership
Funds ownership: 37.6% → 32.06% (-5.5%)
11% less capital invested
Capital invested by funds: $5.65M → $5.03M (-$621K)
43% less funds holding
Funds holding: 30 → 17 (-13)
82% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 11
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
P
Pfizer
New York
|
+$756K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$447K |
| 2 |
Renaissance Technologies
New York
|
-$70.2K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$69K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$54.3K |
| 5 |
AC
Armistice Capital
New York
|
-$47.8K |
NXTC Hedge Fund Activity: Q3 2025 in Review
17 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q3 2025, worth a combined $5.03M — down 11% from $5.65M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NXTC and 0 opened new positions — a net loss of 13 holders — while 11 trimmed existing stakes and 2 added.
The largest buyer was Pfizer, adding an estimated $756K. The largest seller was Citigroup, cutting an estimated $447K.
- 17 institutional investors held NextCure (NXTC) as of Q3 2025, down from 30 in Q2 2025.
- Funds reported $5.03M of NextCure stock for Q3 2025, down 11% quarter-over-quarter.
- 0 funds opened new NextCure positions in Q3 2025 and 13 closed out, a net change of -13 holders.
- The largest NextCure buyer in Q3 2025 was Pfizer, an estimated $756K added.
- The largest NextCure seller in Q3 2025 was Citigroup, an estimated $447K sold.
Based on aggregated 13F filings for Q3 2025.